Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, ...

A study led by researchers at Queen Mary University of London has found that hormone replacement therapy (HRT) may help ...

A study led by researchers at Queen Mary University of London has found that hormone replacement therapy (HRT) may help ...

() -Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.-based company's experimental drug, ...

Nanomedicine uses ultra-small particles to deliver drugs directly to the tissues and cells that need them, improving ...

Omeros stock jumps 164% as Novo Nordisk acquires global rights to zaltenibart, with potential milestones reaching $2.1 ...

Omeros Corporation maintained with Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for ...

UD researchers study how protein coatings influence nanoparticles' ability to avoid immune clearance and reach their ...

Neil Bressler, M.D., a professor of ophthalmology at Johns Hopkins and editor-in-chief of JAMA Ophthalmology, argued that complement inhibition for geographic atrophy is a game changer. His debating ...

Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.